| Project/Area Number |
17K15017
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
ten Dijke Peter
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | Macrocyclic peptides / In vitro selection / RaPID system / angiogenesis / macrocyclic peptide / ALK1 / BMP signaling / in vitro selection / macrocyclic peptides / ALK1 receptor / tumor angiogenesis / cancer signaling |
|---|
| Outline of Final Research Achievements |
We performed the RaPID selection against the BMP receptor ALK1 and isolated the macrocyclic peptide ALK1-3R6-5. We characterized ALK1-R6-5 using biolayer interferometry, in vitro inhibition assays, and pull-down assays. Our conclusion is that ALK1-3R6-5 is too small for our experiments. I have produced a monobody library to address this problem. This library is based on the scaffold of fibronectin, which has a larger and better-defined structure. We have validated production of the library and are currently in the process of performing selection for ALK1-binding monobodies.
|
| Academic Significance and Societal Importance of the Research Achievements |
The significance of our findings brings us closer to inhibiting tumor growth in cancer. We learned that regulation of the ALK1 receptor and subsequent inhibition of angiogenesis requires a ligand larger than a macrocyclic peptide and we are now developing monobodies against ALK1.
|
